An acquisition of Neuren at the price Biogen paid to acquire Reata would translate to ~ A$90 per share.
Whether one considers that Biogen overpaid for Reata or not, it’s worth remembering that the other bidding party was willing to pay almost as much and that the very first bid by the other pharma, before the bidding war commenced, would still translate to a ~A$73 per share bid for Neuren.
So there was not one, but two pharma, willing to “overpay” for Reata’s CNS rare disease asset.
NEU Price at posting:
$13.32 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)